Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geron Q2 Revenue Increases
Geron said that the revenues for the second quarter and year to date period of 2010 reflect funding from collaboration agreements and royalty and license fee revenues under
Geron said that the revenues for the second quarter and year to date period of 2010 reflect funding from collaboration agreements and royalty and license fee revenues under
Acadia Pharma is expected to recruit approximately 200 patients at clinical sites located in North America. Patients in the trial will be randomised on a one-to-one basis to
Most recently, Dr Miller has served as a chief medical officer of PTC Therapeutics and led the strategic design and implementation of development activities for the company’s clinical-stage
Shionogi said that Cuvposa is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Cuvposa indirectly reduces the rate of salivation
Devax claimed that its Axxess System technology is a proprietary self-expanding Nitinol stent specifically designed for the treatment of coronary and vascular bifurcation lesions. The conical shape of
Abraxane is a solvent-free chemotherapy treatment option for metastatic breast cancer which was developed using Abraxis BioScience’s proprietary nab technology platform. Abraxis BioScience said that it has granted
Abbott said that Simcor is a prescription medication used along with diet in people who cannot control their cholesterol levels by diet and exercise alone. Simcor is approved
A5 Labs said that its patent application describes its new method for producing therapeutic proteins as well as specifically providing details of the production of its product VI-1718.
In the trial, Teva has evaluated the efficacy and safety of Beclomethasone dipropionate (BDP) HFA nasal aerosol in the treatment ofSAR. Teva’s Phase III SAR trial was a
Nektar Therapeutics has posted a net loss of $517m for the second quarter 2010, or $0.01 loss per diluted share, compared to net loss of $32.1m, or $0.35